Does Sharp Health Plan Cover Forteo?

What Sharp Health Plan Actually Says About Forteo

Sharp Health Plan does not publish a single universal formulary that applies to every member. Sharp operates HMO, PPO, and Medicare Advantage plans, each with its own drug formulary and medical-benefit rules. Forteo is a specialty-tier injectable that almost always requires prior authorization regardless of which Sharp plan you hold.

The fastest way to get a definitive answer is a three-step check: (1) log into the Sharp Health Plan member portal and search the drug formulary for "teriparatide" or "Forteo," (2) call the pharmacy benefits number on the back of your member ID card, and (3) ask your prescribing physician's office to initiate a prior authorization request simultaneously.

Why Prior Authorization Exists for Teriparatide

Teriparatide costs roughly $3,000 per month at list price, placing it in the specialty tier of nearly every commercial formulary. Payers require prior authorization to confirm that the clinical criteria for an anabolic bone agent have been met before approving a drug in this cost class.

The FDA approved teriparatide in 2002 under NDA 021318 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and adults with glucocorticoid-induced osteoporosis. [1] That approval was based on demonstrating anabolic bone formation, a mechanism distinct from bisphosphonates, which makes teriparatide a step-therapy drug rather than a first-line agent in most payer guidelines.

Typical Sharp Prior Authorization Criteria

While Sharp does not publish its exact clinical criteria publicly, commercial and Medicare Advantage plans in California generally align with industry-standard criteria for anabolic osteoporosis agents. Expect to document:

• A DXA T-score of -2.5 or below at the lumbar spine or hip, or a T-score of -1.5 or below with one or more fragility fractures
• Documented intolerance to, contraindication to, or treatment failure with at least one oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly being the most common)
• Absence of conditions contraindicated with teriparatide, including Paget disease of bone, unexplained alkaline phosphatase elevation, prior external beam radiation to the skeleton, or open epiphyses
• Prescriber attestation that the treatment duration will not exceed 24 cumulative months, per the FDA label [1]

The Clinical Case for Teriparatide: Why Plans Cover It at All

Understanding why insurers cover Forteo at all requires understanding what it does that bisphosphonates cannot. Bisphosphonates reduce bone resorption. Teriparatide, a recombinant fragment of human parathyroid hormone (PTH 1-34), stimulates new bone formation by acting on osteoblasts. [2]

Fracture Reduction Data

The key trial supporting FDA approval enrolled 1,637 postmenopausal women with prior vertebral fracture. Teriparatide 20 mcg/day reduced the risk of new vertebral fractures by 65% (relative risk 0.35; 95% CI 0.22 to 0.55; P<0.001) compared with placebo over a median of 21 months. [3] Non-vertebral fragility fracture risk fell by 53% (P<0.02). [3]

Lumbar spine BMD increased by a mean of 9.7% from baseline in the teriparatide group versus 2.4% in the placebo group at 18 months (P<0.001). [3] Those numbers matter for your prior authorization appeal: they are the clinical justification your prescriber can cite.

Head-to-Head Versus Bisphosphonate

The VERO trial (N=1,360 postmenopausal women with osteoporosis and prior fracture) compared teriparatide 20 mcg/day directly against risedronate 35 mg/week over 24 months. Teriparatide produced 56% fewer new vertebral fractures (P<0.0001) and 52% fewer clinical fractures (P=0.0042). [4] Citing VERO in a prior authorization appeal for a patient who has already fractured on a bisphosphonate is clinically appropriate.

Who Is the Ideal Candidate

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines position teriparatide as a preferred agent for patients at "very high" fracture risk, defined as a FRAX 10-year hip fracture probability above 4.5% with a recent fracture, or a T-score below -3.0 with risk factors. [5] The AACE guidelines state directly: "Anabolic therapy should be considered first in very high-risk patients because it reduces fracture risk more rapidly than antiresorptive therapy." [5]

How to Get Sharp Health Plan to Approve Forteo

Getting prior authorization approved is a documentation exercise. The more specific and complete the submission, the fewer rounds of appeal your prescriber will need.

Step 1: Confirm Your Plan's Formulary Tier

Log into the Sharp member portal at sharp.com or call member services. Ask specifically whether teriparatide (the generic name) appears on your formulary and at what tier. Some Sharp Medicare Advantage plans place it on Tier 4 (specialty), others on Tier 5 (select specialty). The tier determines your cost-share after approval.

Step 2: Gather Required Documentation

Your prescriber's office should compile:

• A DXA scan report dated within the last 24 months showing T-scores at lumbar spine and total hip
• A FRAX fracture risk calculation printed from the WHO FRAX tool [6]
• Documentation of bisphosphonate trial (drug name, dose, duration, reason for discontinuation or failure)
• Relevant fracture imaging (X-ray, CT, or MRI reports confirming vertebral or non-vertebral fracture if applicable)
• Serum calcium, creatinine, and alkaline phosphatase results to rule out contraindications

Step 3: Submit and Track

Most Sharp prior authorization requests resolve within 3 to 5 business days for non-urgent cases. Urgent requests (active fracture, high fall risk) may be processed within 72 hours under California Department of Managed Health Care rules. [7] If denied, you have the right to an internal appeal and, after that, an Independent Medical Review through the DMHC.

Step 4: Use the Manufacturer's Patient Assistance Program

If coverage is denied while you appeal, Eli Lilly's Lilly Cares Foundation offers Forteo at reduced or no cost for qualifying patients. Your prescriber's office can initiate enrollment simultaneously with the insurance appeal to avoid a treatment gap.

Biosimilar and Alternative Options Sharp May Prefer

Sharp, like many California plans, may prefer or require trial of lower-cost alternatives before approving brand Forteo. Knowing these options helps you anticipate the step-therapy requirements.

Generic Teriparatide

The FDA approved the first generic teriparatide (Brixia, Alvogen) in 2023. [8] Generic teriparatide delivers the same 20 mcg/day PTH 1-34 dose via a prefilled pen. If your Sharp formulary lists "teriparatide" without specifying the brand, the generic version is likely what will be dispensed, at a lower specialty-tier cost-share.

Abaloparatide (Tymlos)

Abaloparatide is a PTH-related protein analog approved by the FDA in 2017 for postmenopausal osteoporosis. [9] The ACTIVE trial (N=2,463) showed abaloparatide reduced vertebral fracture risk by 86% versus placebo (P<0.001) and increased lumbar spine BMD by 11.2% at 18 months. [10] Some Sharp formularies tier abaloparatide differently from teriparatide. If your plan prefers abaloparatide as the first anabolic agent, it may be clinically equivalent and easier to approve.

Romosozumab (Evenity)

Romosozumab is a sclerostin inhibitor that both builds bone and reduces resorption. The FDA approved it in 2019 for postmenopausal women at high fracture risk. [11] The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared with alendronate alone (P<0.001). [12] Romosozumab carries a black box warning for cardiovascular events and is contraindicated within 12 months of myocardial infarction or stroke. [11] If your plan requires romosozumab before Forteo, that cardiovascular history review becomes medically relevant.

Why Bisphosphonates Come First

Alendronate 70 mg once weekly remains the first-line agent in virtually every payer's step-therapy protocol because its fracture reduction evidence spans over two decades and its generic cost is under $10 per month. The FIT trial (N=2,027) showed alendronate reduced vertebral fracture risk by 47% (P<0.001) over 3 years in postmenopausal women with prior fracture. [13] Most Sharp plans require a documented 3- to 6-month trial of alendronate or risedronate before approving any anabolic agent.

What the 24-Month Lifetime Cap Means for Your Treatment Plan

The FDA label for Forteo limits cumulative lifetime use to 24 months. [1] This cap exists because teriparatide increased the incidence of osteosarcoma in rats at suprapharmacologic doses in preclinical studies, though post-marketing surveillance in humans over 20-plus years has not established a causal link to osteosarcoma. [14]

The clinical implication: teriparatide is a time-limited anabolic "window." After completing a course, a follow-on antiresorptive agent (typically a bisphosphonate or denosumab) is required to preserve the BMD gains. The Endocrine Society 2019 guideline states: "Patients who complete teriparatide therapy should receive antiresorptive therapy to maintain gains in BMD." [15]

For Sharp prior authorization purposes, your prescriber should state in the request that follow-on antiresorptive therapy is planned. This demonstrates medically appropriate sequencing and may reduce reviewer skepticism about the total treatment cost.

Monitoring During Treatment

Patients on teriparatide should have:

• Serum calcium checked within 1 to 4 weeks of initiation (teriparatide transiently raises calcium 4 to 6 hours post-injection)
• DXA at 12 months to confirm anabolic response (lumbar spine BMD increase of 3% or more is the typical response threshold)
• 24-hour urine calcium if hypercalciuria is suspected

Sharp's medical management team may require these monitoring labs to renew the authorization at 12 months if the initial approval covers only the first year.

Appeals and External Review Rights in California

California law under the Knox-Keene Act gives Sharp Health Plan members specific appeal rights. [7] If your Forteo prior authorization is denied:

• You have 180 days to file an internal grievance.
• Sharp must respond to an urgent appeal within 72 hours and a standard appeal within 30 days.
• If the internal appeal is denied, you may request an Independent Medical Review (IMR) through the California Department of Managed Health Care. The IMR is binding on Sharp.
• A 2022 DMHC analysis found that IMR decisions overturned insurer denials in approximately 30% of osteoporosis-related pharmacy cases reviewed.

Your prescriber's clinical letter citing the VERO trial data [4] and AACE guideline positioning [5] should accompany every level of appeal.

Cost-Share Estimates if Coverage Is Approved

If Sharp approves Forteo, your out-of-pocket cost depends on your plan tier and benefit design. Specialty-tier cost-share in California commercial plans typically runs 20% to 33% coinsurance with a per-month cap that varies by plan. For a drug with a $3,000 list price, 20% coinsurance equals $600 per month before any manufacturer copay assistance applies.

Eli Lilly's Forteo savings card may reduce commercial plan cost-share to as low as $4 per month for eligible patients (income and insurance status criteria apply). Medicare Part D members are not eligible for manufacturer copay cards under federal anti-kickback rules, but the Low Income Subsidy (Extra Help) program may reduce cost-share significantly for qualifying Medicare beneficiaries.

Talking to Your Prescriber Before the Visit

Coming to your appointment with specific information accelerates the process. Bring:

• Your Sharp member ID card (the pharmacy benefit number is on the back)
• Your most recent DXA report
• A list of all bone medications you have tried, with dates and reasons for stopping
• Any fracture history with imaging dates

A prescriber who documents "T-score -2.9 at L2-L4, prior vertebral fracture at T12 confirmed on MRI dated June 2024, intolerance to alendronate due to esophageal stricture" will get a faster approval than one who writes "severe osteoporosis, bisphosphonate failure."

Serum 25-hydroxyvitamin D should be at or above 30 ng/mL before starting teriparatide, per AACE guidance. [5] Low vitamin D blunts the anabolic response and may prompt a plan reviewer to question clinical readiness.